Ty-82Homo sapiens (Human)Cancer cell line
Also known as: Ty82, TY82, TY-82
🤖 AI SummaryBased on 4 publications
Quick Overview
Human thymic carcinoma cell line with t(15;19) chromosomal abnormality
Detailed Summary
Ty-82 is a human thymic carcinoma cell line established from a 22-year-old female patient with an undifferentiated thymic carcinoma. The cell line exhibits a complex chromosomal rearrangement involving the t(15;19)(q15;p13) abnormality, which is characteristic of NUT midline carcinoma (NMC). This cell line has been used in research to study the genetic and molecular mechanisms underlying NMC, including the role of BRD4-NUT fusion oncogenes in tumorigenesis. Ty-82 cells show features of anaplastic carcinoma, with no expression of typical epithelial markers and resistance to conventional chemotherapy. The cell line has been utilized in studies involving chromosomal analysis, immunophenotyping, and in vivo tumor formation in xenograft models.
Research Applications
Genomic and chromosomal analysisImmunophenotypingIn vivo tumor formation (xenograft models)Study of BRD4-NUT fusion oncogenes
Key Characteristics
Carries t(15;19)(q15;p13) chromosomal abnormalityExpresses BRD4-NUT fusion proteinAnaplastic morphology with no epithelial differentiationResistant to conventional chemotherapy
Generated on 6/20/2025
Basic Information
| Database ID | CVCL_3220 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pleural effusion[UBERON:UBERON_0000175] |
Donor Information
| Age | 22 |
|---|---|
| Age Category | Adult |
| Sex | Female |
Disease Information
| Disease | Thymic carcinoma |
|---|---|
| Lineage | Head and Neck |
| Subtype | NUT Midline Carcinoma of the Head and Neck |
| OncoTree Code | NMCHN |
DepMap Information
| Source Type | JCRB |
|---|---|
| Source ID | ACH-001676_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene fusion | BRD4 | BRD4-NUTM1, BRD4-NUT | - | BRD4 exon 14 fused to NUTM1 exon 2 | PubMed=29348827, PubMed=28203693, PubMed=24736545 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X
CSF1PO
11,12
D13S317
11
D16S539
9,11
D5S818
9,11
D7S820
12,13
TH01
6,9.3
TPOX
9,11
vWA
17,19
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease.
Stirnweiss A., Oommen J., Kotecha R.S., Kees U.R., Beesley A.H.
Oncotarget 8:112313-112329(2017).
Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma.
Koo S.H., Keam B., Jeon Y.K., Ku J.-L., Yang F.-T., Kim T.M., Ju Y.S.
Ann. Oncol. 28:890-897(2017).
Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.
Janicki S.M., French C.A., You J.-X.
Cancer Res. 74:3332-3343(2014).
Differentiation of NUT midline carcinoma by epigenomic reprogramming.
Sallan S.E., Kung A.L., Bradner J.E., French C.A.
Cancer Res. 71:2686-2696(2011).